Trial Profile
A Phase II Study of Pevonedistat (MLN4924, TAK924) and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission Acute Myelogenous Leukemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2020
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Pevonedistat (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 26 Feb 2020 Status changed from suspended to discontinued.
- 17 Oct 2019 Status changed from recruiting to suspended.
- 25 Oct 2018 New trial record